Sanofi-Aventis said today it lost a patent infringement case against two generic drug makers involving its top-selling product, the blockbuster bloodthinner Lovenox. Amphastar Pharmaceuticals and Teva ...

Emphasizing the tenet that antitrust laws are enacted to protect ­competition—and not competitors—the Third Circuit has rejected one competitor's claim that Sanofi-Aventis had an unfair advantage in ...

Unlike unfractionated heparin (UFH), the low-molecular-weight heparin enoxaparin (Lovenox) is excreted mainly by the kidneys. To determine whether this characteristic heightens bleeding risk in ...

Sanofi’s big-selling blood thinner Lovenox has long faced generic competition in the U.S., but now rival generics makers are squashing long-running lawsuits over their own versions of the drug.

Sanofi-Aventis is suing FDA, claiming the agency acted inconsistently and unlawfully in approving a generic version of its anticoagulant Lovenox. The approval of the generic, developed by Momenta ...

If you have deep vein thrombosis or a pulmonary embolism, or if you had a certain kind of heart attack (among other conditions), your doctor may prescribe the blood thinner enoxaparin (Lovenox), per ...

Sanofi-Aventis' anti-blood clot drug Lovenox reduced the risk of repeat heart attacks and deaths among people who suffered a major heart attack in a new study discussed at the annual scientific ...